Lilly's Orforglipron Shows Superiority in Phase 3 Diabetes Trials

Eli Lilly has made significant strides with its oral diabetes medication, orforglipron, often described as 'Ozempic-in-a-pill.' The company announced that this experimental once-daily pill has successfully met all primary and secondary endpoints in two key Phase 3 clinical trials: ACHIEVE-2 and ACHIEVE-5. The results indicate that orforglipron provides superior glycemic control when compared to a standard SGLT-2 inhibitor and a placebo, highlighting its potential impact on diabetes management.

Released in October 2025, findings showed that orforglipron led to substantial reductions in A1C levels, which measure average blood sugar, as well as a decrease in body weight over a 40-week timeframe. One notable aspect of orforglipron is its classification as a non-peptide small-molecule drug. Unlike conventional oral GLP-1 treatments, which are peptide-based and can be broken down by stomach enzymes, orforglipron's stability allows it to be absorbed effectively as a pill without stringent dietary restrictions concerning food or water intake.

Orforglipron is categorized within the GLP-1 (glucagon-like peptide-1) receptor agonist class, functioning by mimicking a gut hormone that stimulates insulin release and slows gastric emptying. This contrasts with SGLT-2 inhibitors, which operate by expelling excess glucose through the kidneys. Data from recent trials suggest that the hormonal mechanism of orforglipron offers more robust glycemic control compared to renal-focused treatments.

The comprehensive ACHIEVE program evaluates orforglipron across five global registration trials. Previous studies had indicated that it outperformed oral semaglutide, but the results from ACHIEVE-2 and ACHIEVE-5 provide definitive evidence of its superiority over current standard treatments for diabetes.

In terms of secondary benefits, orforglipron has been associated with improvements in cardiovascular risk factors. Its safety profile remains consistent with the wider GLP-1 class, with the most commonly reported side effects being mild-to-moderate gastrointestinal disturbances, while no liver safety issues were identified.

The ACHIEVE-2 trial specifically compared orforglipron to the SGLT-2 inhibitor dapagliflozin among patients inadequately controlled on metformin. Those administered a 36 mg dose of orforglipron experienced an A1C reduction of 1.7%, significantly exceeding the 0.8% reduction seen in the SGLT-2 group.

Jeff Emmick, senior vice president of product development at Lilly Cardiometabolic Health, remarked, “Orforglipron has now demonstrated superiority over two active comparators,” underlining its potential as a new benchmark in diabetes care.

The ACHIEVE-5 trial examined adults on titrated insulin glargine, adjusting doses to maintain fasting blood sugar stability. This study is notable as it illustrated that incorporating orforglipron with insulin glargine resulted in an additional A1C decrease of 2.1%, compared to just 0.8% in the placebo group. This is crucial for many individuals whose blood sugar control is insufficient with insulin alone or who face challenges such as weight gain associated with insulin therapy. Thus, orforglipron has the dual benefit of aggressive blood sugar management alongside weight loss promotion.

Overall, Lilly plans to submit orforglipron for regulatory approval in 2026. If authorized, this medication could eliminate the logistical challenges associated with injectable treatments and outdated fasting protocols, providing a flexible oral option for the global diabetes community.